

## FACTOR VIII CONCENTRATE (RECOMBINANT)

<b>OTHER NAMES</b>	Factor VIII, Recombinant Factor 8, Factor 8 Concentrate, Antihemophilic Factor (Recombinant), Kogenate® FS**, Advate®**, Adynovate, Eloctate®, Helixate® FS**, Kovaltry™, Nuwq®, OBIZUR®, Xyntha®, Xyntha® Solofuse® *OBIZUR is a recombinant porcine factor VIII **these products are no longer manufactured
<b>PRODUCT COMPOSITION</b>	Antihemophilic Factor is a sterile, purified, lyophilized concentrate which has been manufactured by recombinant DNA technology. The concentration of Factor VIII (IU) will vary depending on the manufacturer and specific lot number. Factor VIII concentrate is cell free and therefore is administered without regard to patient ABO or Rh type.
<b>INFORMED CONSENT</b>	Not required
<b>ALTERNATIVES</b>	<b>Non-blood Product:</b> None <b>Blood Product:</b> None
<b>DOSAGE</b>	<ul style="list-style-type: none"> <li>Dosage and duration of treatment will depend on the patient factor deficiency and the circumstances necessitating the treatment</li> <li>The manufacturer product monograph will provide specific dosage guidelines</li> <li>Ordered as IU (international units) and a timed frequency (e.g. Q2h)</li> <li>Transfusion Medicine (TM) will provide the dose requested <math>\pm 10\%</math> depending on available vial sizes</li> </ul>
<b>ADMINISTRATION</b>	<ul style="list-style-type: none"> <li>Reconstituted and filtered by TM and supplied to unit in a syringe</li> <li>Product is best given immediately after preparation, <b>MUST</b> be within 3 hours of reconstitution</li> <li>Should be inspected visually for particulate matter and discoloration prior to administration</li> <li>Should be given IV direct push, recommended over 3 to 5 minutes – see product insert for specific administration rate guidelines</li> <li>Flush tubing pre- and post-infusion with 0.9% NaCl</li> <li><b>Administer the entire amount</b></li> </ul>
<b>DIAGNOSTIC MONITORING</b>	<b>Vital sign monitoring as per hospital policy for any blood, blood component and other related product.</b> In the event of an immediate or suspected transfusion reaction, refer to hospital policy and procedures.
<b>CLINICAL INDICATIONS</b>	<ul style="list-style-type: none"> <li>Indicated for the perioperative management as well as the prevention and control of bleeding which may occur in patients with the genetic bleeding disorder Hemophilia A (Classical Hemophilia)</li> </ul>
<b>SPECIAL CONSIDERATIONS</b>	<ul style="list-style-type: none"> <li>TM will need approximately 30 minutes preparation time</li> <li>TM needs prompt notification of changes of both dosage and/or frequency</li> <li>Continuous infusion: under certain circumstances, a continuous infusion may be requested by the physician, phone Transfusion Medicine (local 68003) if such an order is made</li> </ul>
<b>STORAGE CONDITIONS</b>	DO NOT REFRIGERATE AFTER RECONSTITUTION
<b>REFERENCES</b>	<b>Review product monograph</b>